ADC Therapeutics Ltd (ADCT)

ADC Therapeutics SA's stock has increased by 202.96% in the past six months. In June 2025, the company announced positive data from the LOTIS-7 Phase 1b trial, showing high response rates for ZYNLONTA in combination with glofitamab. In May 2025, ADC Therapeutics closed its UK research site and laid off 30% of its workforce after dropping a clinical-stage candidate. In October 2025, the company announced a $60.0 million private investment in public equity (PIPE) financing to support ZYNLONTA's commercial expansion and strengthen its balance sheet. Also in October 2025, HC Wainwright lowered their price objective on ADC Therapeutics from $8.00 to $7.00, while maintaining a "buy" rating. In November 2025, the company announced participation in three upcoming investor conferences.

Information regarding specific demand seasonality for ADC Therapeutics SA's products and services was not found. Demand is likely driven by disease incidence, diagnosis rates, and treatment protocols, rather than typical seasonal fluctuations.

ADC Therapeutics SA is a commercial-stage biotechnology company focused on discovering, developing, and commercializing targeted antibody-drug conjugates (ADCs) for hematologic malignancies and solid tumors. Their flagship product, ZYNLONTA, is approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after multiple lines of systemic therapy. The company is also exploring ZYNLONTA's potential in combination therapies and earlier treatment lines. ADC Therapeutics has a pipeline of other investigational ADCs, including compounds targeting CD-22 and ADCT-602 for B-cell acute lymphoblastic leukemia, as well as ADCT-601 for sarcoma, pancreatic, and non-small cell lung cancer. Their preclinical pipeline features next-generation ADCs targeting Claudin-6, NaPi2b, PSMA, and ASCT2.

ADC Therapeutics SA is headquartered in Epalinges, Switzerland, and maintains operations in London and New Jersey (USA).

ADC Therapeutics' brand reputation has been influenced by positive clinical data from the LOTIS-7 trial and strategic financing through a $60 million private placement. Analyst coverage has been mixed, with some reiterating "Buy" ratings and others issuing "Sell" ratings. Restructuring and layoffs in May 2025 may have negatively impacted employee morale and public perception. Regular participation in investor and healthcare conferences helps maintain visibility within the industry.

ADC Therapeutics SA has a diverse ownership base, with institutional investors holding a significant stake of 32%. Major institutional owners include Redmile Group, LLC, Prosight Management, LP, Point72 Asset Management, L.P., Orbimed Advisors Llc, BlackRock, Inc., Morgan Stanley, Heights Capital Management, Inc, Nantahala Capital Management, LLC, Bank Of America Corp /de/, and Goldman Sachs Group Inc.